In the US, Nivolumab (nivolumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Colorectal Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Urothelial Carcinoma.
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Inhibitor of PD-1 proteins
A genetically engineered, fully human immunoglobulin G4 (IgG4) mA anti programmed death-1/PD-1 antibody.
Immunoglobulin G4-kappa, anti-[Homo sapiensPDCD1 (programmed cell death 1, PD-1, PD1, CD279)], Homo sapiensmonoclonal antibody; gamma4 haevy chain (1-440) [Homo sapiensVH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (WHO)
- Nivolumabum (Latin)
- Nivolumab (German)
- Nivolumab (French)
- Nivolumab (Spanish)
- Nivolumab (OS: USAN, JAN)
- BMS-936558 (IS)
- MDX-1106 (IS)
- UNII-31YO63LBSN (IS)
- Nivolumab BMS
Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb Pharmaceutical, United Kingdom
Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, France; Bristol-Myers Squibb, United States; Bristol-Myers Squibb Pharmaceutical, United Kingdom
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Click for further information on drug naming conventions and International Nonproprietary Names.